These mechanistic and translational data together explain why interventions that selectively perturb the Bcl-2:beclin-1 axis (for example, phosphorylation modulators or BH3-mimetics that alter specific protein–protein interactions) are being explored as strategies to tip the balance toward glioma cell death. This evidence concerns the gene BCL2 and central nervous system cancer.